Circulating microRNAs to choose the IO strategy in PD-L1≥50% NSCLC patients.
Ente Finanziatore: Ministero della Salute (Ricerca Corrente) e 5x1000
Principal Investigator: Dott.ssa Proto Claudia
Co Principal Investigator: Dott. Boeri Mattia
Data di inizio:
Data di fine:
Struttura Principale: Chirurgia Toracica
We identified a microRNA signature (MSC) predicting ICI response. The Ark trial will randomize PD-L1≥50% NSCLC patients with high-risk MSC to ICI single agent or ICI+chemotherapy to assess efficacy, also analyzing additional biomarkers.
Principal Investigator Dr. Proto Claudia
Co Principal Investigator Dott. Boeri Mattia
Struttura Principale: Thoracic Surgery Unit
Clinical Area, Complex Structure
Translational Immunology Unit
Research Area, Simple Structure
Anatomia patologica 2
Struttura complessa
Last update: 23/10/2025